Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the ...

Discover the latest drugs and treatment options in the Psoriasis Pipeline. Dive into DelveInsight's comprehensive report ...

Analysts at HC Wainwright issued their FY2029 EPS estimates for Galectin Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst E. Arce expects that the company will post ...

Galectin Therapeutics (NASDAQ:GALT – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (GALT) (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial ...

(MENAFN- GlobeNewsWire - Nasdaq) NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins ...